Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups
Susana Vives,David Quintela,Mireia Morgades,Isabel Cano-Ferri,Alfons Serrano,Evelyn Acuna-Cruz,Marta Cervera,Marina Diaz-Beya,Belen Vidriales,Jose angel Raposo-Puglia,Montserrat Arnan,Ana Garrido, Amaia Balerdi, Ana Isabel Cabello,Pilar Herrera-Puente,Josefina Serrano,Rosa Coll,Mar Tormo,Javier Lopez-Marin,Sara Garcia-avila, Maria Soledad Casado,Irene Padilla,Gabriela Rodriguez-Macias,Maria Calbacho, Ana Puchol, Agustin Hernandez,Melissa Torres, Lissette Costilla, Maria Mercedes Colorado,David Martinez-Cuadron,Jordi Esteve,Pau Montesinos, CETLAM Grp, PETHEMA Grp CANCERS（2024）
Key words
FLT3 mutations,acute myeloid leukemia,gilteritinib,quizartinib,real world data
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper